Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Cash from Operations: 2023-2025

Historic Cash from Operations for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -$7.3 million.

  • Mereo BioPharma Group's Cash from Operations rose 2.79% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.7 million, marking a year-over-year decrease of 8.30%. This contributed to the annual value of -$32.8 million for FY2024, which is 55.38% down from last year.
  • As of Q3 2025, Mereo BioPharma Group's Cash from Operations stood at -$7.3 million, which was up 4.47% from -$7.7 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's Cash from Operations registered a high of $2.7 million during Q3 2023, and its lowest value of -$9.4 million during Q4 2024.
  • In the last 3 years, Mereo BioPharma Group's Cash from Operations had a median value of -$7.8 million in 2023 and averaged -$7.0 million.
  • Over the last 5 years, Mereo BioPharma Group's Cash from Operations had its largest YoY gain of 13.59% in 2024, and its largest YoY loss of 382.78% in 2024.
  • Quarterly analysis of 3 years shows Mereo BioPharma Group's Cash from Operations stood at -$6.8 million in 2023, then tumbled by 38.75% to -$9.4 million in 2024, then climbed by 2.79% to -$7.3 million in 2025.
  • Its last three reported values are -$7.3 million in Q3 2025, -$7.7 million for Q2 2025, and -$8.3 million during Q1 2025.